stockrow
Friday 6 November 2026
Export BCLI’s income statement to Excel — free account
Brainstorm Cell Therapeutics Inc.
BCLI Healthcare Biotechnology
- EPS
- −2.94%
- Free cash flow
- +74.4%
- Total debt
- +1,148.5%
Quarter to June 2026, against a year earlier
0.90
0.04
+4.65%
Follow BCLI
Alert me
Brainstorm Cell Therapeutics Inc. (BCLI) P/E ratio
Brainstorm Cell Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KPRX Kiora Pharmaceuticals, Inc. compare | n/m |
| XTLB XTL Biopharmaceuticals Ltd. compare | n/m |
| MTVA MetaVia Inc. compare | n/m |
| IMRN IMMURON compare | n/m |
| SNGX Soligenix Inc. compare | n/m |
| ENSC Ensysce Biosciences, Inc. compare | n/m |
| SYBX Synlogic, Inc. compare | n/m |
| VTGN VistaGen Therapeutics, Inc. compare | n/m |
| BCLI Brainstorm Cell Therapeutics Inc. | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)